These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30244616)

  • 1. Is probiotic use beneficial for skin lesions in patients with inflammatory bowel disease?
    Satta R; Pes GM; Rocchi C; Pes MC; Dore MP
    J Dermatolog Treat; 2019 Sep; 30(6):612-616. PubMed ID: 30244616
    [No Abstract]   [Full Text] [Related]  

  • 2. Concomitant occurrence of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease.
    Goldberg I; Finkel O; Gat A; Sprecher E; de Morentin HM
    Isr Med Assoc J; 2014 Mar; 16(3):168-70. PubMed ID: 24761705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
    J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease.
    Vavricka SR; Galván JA; Dawson H; Soltermann A; Biedermann L; Scharl M; Schoepfer AM; Rogler G; Prinz Vavricka MB; Terracciano L; Navarini A; Zlobec I; Lugli A; Greuter T
    J Crohns Colitis; 2018 Feb; 12(3):347-354. PubMed ID: 29182760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cutaneous manifestations in inflammatory bowel disease].
    Chavez-Álvarez S; Gómez-Flores M; Ocampo-Candiani J
    Gac Med Mex; 2016; 152(5):622-630. PubMed ID: 27792697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
    Roth N; Biedermann L; Fournier N; Butter M; Vavricka SR; Navarini AA; Rogler G; Scharl M;
    PLoS One; 2019; 14(1):e0210436. PubMed ID: 30682031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease.
    Ciccacci C; Biancone L; Di Fusco D; Ranieri M; Condino G; Giardina E; Onali S; Lepre T; Pallone F; Novelli G; Borgiani P
    J Crohns Colitis; 2013 Feb; 7(1):44-52. PubMed ID: 22445837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients.
    Farhi D; Cosnes J; Zizi N; Chosidow O; Seksik P; Beaugerie L; Aractingi S; Khosrotehrani K
    Medicine (Baltimore); 2008 Sep; 87(5):281-293. PubMed ID: 18794711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cutaneous and mucosal manifestations of inflammatory bowel diseases].
    Károlyi Z; Erós N; Ujszászy L; Nagy G
    Orv Hetil; 2000 Jun; 141(25):1391-5. PubMed ID: 10934882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.
    King D; Chandan JS; Thomas T; Nirantharakumar K; Reulen RC; Adderley NJ; Trudgill N
    Inflamm Bowel Dis; 2021 Oct; 27(11):1731-1739. PubMed ID: 34669933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dermatologic Manifestations in Inflammatory Bowel Disease].
    Suh HY; Lee WJ; Na SY
    Korean J Gastroenterol; 2019 May; 73(5):285-293. PubMed ID: 31132835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
    Juliao-Baños F; Arrubla M; Osorio L; Camargo J; Londoño J; Cáceres C; Carvajal J; Mosquera-Klinger G; Donado J
    Gastroenterol Hepatol; 2021; 44(6):398-404. PubMed ID: 33172691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermatologic manifestations in inflammatory bowel disease in Tunisia.
    Mebazaa A; Aounallah A; Naija N; Cheikh Rouhou R; Kallel L; El Euch D; Boubaker J; Mokni M; Filali A; Ben Osman A
    Tunis Med; 2012 Mar; 90(3):252-7. PubMed ID: 22481199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study.
    Hedin CR; Mullard M; Sharratt E; Jansen C; Sanderson JD; Shirlaw P; Howe LC; Djemal S; Stagg AJ; Lindsay JO; Whelan K
    Inflamm Bowel Dis; 2010 Dec; 16(12):2099-108. PubMed ID: 20848469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Kilic Y; Kamal S; Jaffar F; Sriranganathan D; Quraishi MN; Segal JP
    Inflamm Bowel Dis; 2024 Feb; 30(2):230-239. PubMed ID: 37042969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical analysis of cutaneous manifestations and related factors in patients with ulcerative colitis].
    Tian Y; Li JX; Wang HH; Li RY; Liu XG
    Zhonghua Nei Ke Za Zhi; 2016 Jul; 55(7):505-9. PubMed ID: 27373283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.
    He R; Zhao S; Cui M; Chen Y; Ma J; Li J; Wang X
    Front Immunol; 2023; 14():1234535. PubMed ID: 37954590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do extraintestinal manifestations predict disease course, severity, and/or activity in IBD?
    Walker D; Orchard T
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S200-1. PubMed ID: 18816647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.